BSX Stock Recent News
BSX LATEST HEADLINES
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is how Boston Scientific (BSX) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO , April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE™ Pulsed Field Ablation (PFA) System* and adjunctive use of the FARAPOINT™ PFA Catheter in patients with persistent atrial fibrillation (AF).
Boston Scientific Corporation BSX posted better-than-expected earnings for the first quarter on Wednesday.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Boston Scientific Corporation (NYSE:BSX ) Q1 2025 Results Conference Call April 23, 2025 8:00 AM ET Company Participants Jon Monson - Senior Vice President, Investor Relations Mike Mahoney - Chairman and Chief Executive Officer Dan Brennan - Executive Vice President and Chief Financial Officer Ken Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Rick Wise - Stifel David Roman - Goldman Sachs Travis Steed - Bank of America Patrick Wood - Morgan Stanley Danielle Antalffy - UBS Josh Jennings - TD Cowen Michael Polark - Wolfe Research Vijay Kumar - Evercore ISI Matt Miksic - Barclays Operator Good morning, and welcome to the Boston Scientific First Quarter 2025 Earnings Call. All participants will be in listen-only mode.
Boston Scientific's first-quarter 2025 performance benefits from the strength of its product portfolio.
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Boston Scientific Corporation BSX on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion.
Shares of Boston Scientific (BSX) rose sharply Wednesday after the firm posted first-quarter results that topped analysts' estimates.